Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Share-based Compensation (2016 - 2025)

Fate Therapeutics (FATE) has disclosed Share-based Compensation for 14 consecutive years, with $5.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation fell 39.39% year-over-year to $5.5 million, compared with a TTM value of $24.9 million through Dec 2025, down 39.94%, and an annual FY2025 reading of $24.9 million, down 39.94% over the prior year.
  • Share-based Compensation was $5.5 million for Q4 2025 at Fate Therapeutics, up from $4.9 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $20.5 million in Q2 2022 and bottomed at $4.9 million in Q3 2025.
  • Average Share-based Compensation over 5 years is $12.1 million, with a median of $11.4 million recorded in 2023.
  • The sharpest move saw Share-based Compensation soared 87.7% in 2021, then plummeted 58.68% in 2025.
  • Year by year, Share-based Compensation stood at $14.6 million in 2021, then skyrocketed by 32.88% to $19.4 million in 2022, then plummeted by 51.14% to $9.5 million in 2023, then dropped by 3.75% to $9.1 million in 2024, then plummeted by 39.39% to $5.5 million in 2025.
  • Business Quant data shows Share-based Compensation for FATE at $5.5 million in Q4 2025, $4.9 million in Q3 2025, and $7.2 million in Q2 2025.